YS Biopharma's PIKA Rabies Vaccine Shows Positive Phase 3 Results
Ticker: LSBWF · Form: 6-K · Filed: Apr 9, 2024 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Ys Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Apr 9, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial, vaccine, biotech, phase-3
TL;DR
YS Bio's PIKA Rabies Vaccine Phase 3 trial hits endpoint, looks good for approval.
AI Summary
YS Biopharma Co., Ltd. announced positive interim results on April 9, 2024, for its pivotal Phase 3 clinical study of the PIKA Rabies Vaccine. The study, conducted in China, met its primary efficacy endpoint, demonstrating non-inferiority to the current standard of care.
Why It Matters
Positive clinical trial results for the PIKA Rabies Vaccine could lead to a new, potentially more effective rabies prevention option, impacting public health and the company's market position.
Risk Assessment
Risk Level: medium — Clinical trial results are promising but not yet final approval, and market adoption is uncertain.
Key Players & Entities
- YS Biopharma Co., Ltd. (company) — Registrant and developer of PIKA Rabies Vaccine
- PIKA Rabies Vaccine (product) — Vaccine under clinical study
- April 9, 2024 (date) — Date of announcement
- China (location) — Location of clinical study
FAQ
What was the primary endpoint of the Phase 3 clinical study for the PIKA Rabies Vaccine?
The primary endpoint was to demonstrate non-inferiority of the PIKA Rabies Vaccine compared to the current standard of care.
When were the interim results of the Phase 3 study announced?
The interim results were announced on April 9, 2024.
Where was the pivotal Phase 3 clinical study conducted?
The pivotal Phase 3 clinical study was conducted in China.
What is the significance of the study meeting its primary efficacy endpoint?
Meeting the primary efficacy endpoint indicates that the PIKA Rabies Vaccine is comparable in effectiveness to the existing standard of care for rabies prevention.
What type of report is this filing?
This filing is a Form 6-K, which is a Report of Foreign Private Issuer.
Filing Stats: 180 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2024-04-09 08:20:37
Filing Documents
- ea0203545-6k_ysbio.htm (6-K) — 8KB
- ea020354501ex99-1_ysbio.htm (EX-99.1) — 12KB
- 0001213900-24-031349.txt ( ) — 22KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. YS Biopharma Co., Ltd. Date: April 9, 2024 By: /s/ Hui Shao Name: Hui Shao Title: Director and Chief Executive Officer 2